Skip to Main Content

Paper Details

Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trial.
Lancet HIV
2
2022
Author NameAffiliation
Oliver LaeyendeckerNational Institute of Allergy and Infectious Diseases, National Institutes of Health, USA Johns Hopkins Univiersity School of Medicine
Sarah FidlerImperial College London, UK NIHR Imperial Biomedical Research Centre
  • 1 - 2

Datasets

Release 1.2